Use of genetic mouse models in the study of diabetic nephropathy

[1]  R. Star,et al.  A simplified method for HPLC determination of creatinine in mouse serum. , 2004, American journal of physiology. Renal physiology.

[2]  G. Jerums,et al.  The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  J. She,et al.  Microarray analysis of gene expression in the kidneys of new- and post-onset diabetic NOD mice. , 2003, Diabetes.

[4]  David W Dunstan,et al.  Prevalence of kidney damage in Australian adults: The AusDiab kidney study. , 2003, Journal of the American Society of Nephrology : JASN.

[5]  Kumar Sharma,et al.  Diabetic kidney disease in the db/db mouse. , 2003, American journal of physiology. Renal physiology.

[6]  V. D’Agati,et al.  RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.

[7]  K. Taniguchi,et al.  Renal Lesions in Spontaneous Insulin-dependent Diabetes Mellitus in the Nonobese Diabetic Mouse: Acute Phase of Diabetes , 2003, Veterinary pathology.

[8]  R. Tilton,et al.  Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. , 2002, Diabetes.

[9]  M. Steffes,et al.  Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products , 2002, Diabetes/metabolism research and reviews.

[10]  M. Steffes,et al.  Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. , 2002, Kidney international.

[11]  C. Shearman,et al.  Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice. , 2001, Metabolism: clinical and experimental.

[12]  B. Weston,et al.  Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. , 2001, The Biochemical journal.

[13]  G. Wolf,et al.  Leptin stimulates type I collagen production in db/db mesangial cells: Glucose uptake and TGF-β type II receptor expression , 2001 .

[14]  Alan W. Stitt,et al.  Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease. , 2000, Kidney international.

[15]  K. Matsushima,et al.  Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. , 2000, Kidney international.

[16]  H. Anders,et al.  Murine Models of Renal Disease: Possibilities and Problems in Studies Using Mutant Mice , 2000, Nephron Experimental Nephrology.

[17]  K. Sharma,et al.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G. King,et al.  Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  M. Cooper,et al.  Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. , 1999, Diabetes.

[20]  M. Cooper,et al.  The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? , 1999, Kidney international.

[21]  M. Cooper,et al.  Pathogenesis, prevention, and treatment of diabetic nephropathy , 1998, The Lancet.

[22]  J. Bernhagen,et al.  An agent cleaving glucose-derived protein crosslinks in vitro and in vivo , 1996, Nature.

[23]  J. Cohen,et al.  Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy. , 1996, Experimental nephrology.

[24]  L. Tartaglia,et al.  Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db Mice , 1996, Cell.

[25]  K. Sharma,et al.  Hyperglycemia and Diabetic Kidney Disease: The Case for Transforming Growth Factor–β as a Key Mediator , 1995, Diabetes.

[26]  F N Ziyadeh,et al.  Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy. , 1995, The Journal of clinical investigation.

[27]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[28]  M. Cohen,et al.  Amelioration of diabetic nephropathy by treatment with monoclonal antibodies against glycated albumin. , 1994, Kidney international.

[29]  K. O. Elliston,et al.  Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.

[30]  G. Striker,et al.  Glomerular lesions in nonobese diabetic mouse: before and after the onset of hyperglycemia. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[31]  O. E. Michaelis,et al.  Animal models of spontaneous diabetic kidney disease , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  G. Jerums,et al.  Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat , 1989, Diabetologia.

[33]  B. Brenner,et al.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. , 1986, The Journal of clinical investigation.

[34]  R. Bressler,et al.  Metabolic Control of Prevention of Nephropathy by 2-Tetradecylglycidate in the Diabetic Mouse (db/db) , 1982, Diabetes.

[35]  R. Bressler,et al.  Prevention of Diabetic Nephropathy by Diet Control in the db/db Mouse , 1981, Diabetes.

[36]  S. Lee,et al.  Early immunopathologic events in experimental diabetic nephropathy: a study in db/db mice. , 1980, Experimental and molecular pathology.

[37]  A. Steinberg,et al.  Diabetes is Associated with Autoimmunity in the New Zealand Obese (NZO) Mouse , 1980, Diabetes.

[38]  K. Gärtner.  Glomerular hyperfiltration during the onset of diabetes mellitus in two strains of diabetic mice (C57BL/6Jdb/db and C57BL/KsJdb/db) , 1978, Diabetologia.

[39]  K. Hummel,et al.  The influence of genetic background on expression of mutations at the diabetes locus in the mouse. I. C57BL/KsJ and C57BL/6J strains , 1972, Biochemical Genetics.

[40]  W. Chick,et al.  Studies in the diabetic mutant mouse. VI. Evolution of glomerular lesions and associated proteinuria. , 1972, The American journal of pathology.

[41]  K P Hummel,et al.  Diabetes, a New Mutafton in the Mouse , 1966, Science.

[42]  Chih-wei,et al.  Overexpression of Transforming Growth Factor-pl mRNA Is Associated With Up-Regulation of Glomerular Tenascin and Laminin Gene Expression in Nonobese Diabetic Mice1 , 2005 .

[43]  L. Denner,et al.  Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. , 2004, Diabetes.

[44]  R. Atkins,et al.  Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. , 2004, Kidney international.

[45]  G. Striker,et al.  Localization of glutamic acid decarboxylase in the kidneys of nonobese diabetic mice. , 1996, Nephron.

[46]  R. Gray,et al.  Picric acid methods greatly overestimate serum creatinine in mice: more accurate results with high-performance liquid chromatography. , 1985, Analytical biochemistry.